Published in J Clin Oncol on November 01, 2005
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol (2010) 8.06
Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol (2011) 6.67
WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer (2013) 6.64
Subtypes of medulloblastoma have distinct developmental origins. Nature (2010) 5.94
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One (2008) 5.86
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol (2010) 4.48
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer (2010) 4.10
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol (2012) 3.88
Medulloblastomics: the end of the beginning. Nat Rev Cancer (2012) 3.01
Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol (2011) 2.82
A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell (2012) 2.15
The clinical implications of medulloblastoma subgroups. Nat Rev Neurol (2012) 2.12
Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. Cancer Cell (2016) 2.12
Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol (2010) 2.04
Medulloblastoma stem cells. J Clin Oncol (2008) 1.71
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
A re-evaluation of the "oncogenic" nature of Wnt/beta-catenin signaling in melanoma and other cancers. Curr Oncol Rep (2010) 1.52
Development and cancer of the cerebellum. Trends Neurosci (2011) 1.47
Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res (2011) 1.33
Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol (2012) 1.33
Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma. PLoS One (2009) 1.33
DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol (2013) 1.27
Children's Oncology Group's 2013 blueprint for research: central nervous system tumors. Pediatr Blood Cancer (2012) 1.14
Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol (2013) 1.12
Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. Neuro Oncol (2008) 1.12
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol (2016) 1.11
Childhood brain tumors: accomplishments and ongoing challenges. J Child Neurol (2008) 1.11
Role of MYC in Medulloblastoma. Cold Spring Harb Perspect Med (2013) 1.10
Expression of the neurogenic basic helix-loop-helix transcription factor NEUROG1 identifies a subgroup of medulloblastomas not expressing ATOH1. Neuro Oncol (2007) 1.10
Molecular diagnostics of CNS embryonal tumors. Acta Neuropathol (2010) 1.09
Treatment of pediatric brain tumors. J Cell Physiol (2008) 1.09
An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET). Br J Cancer (2009) 1.08
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell (2014) 1.08
Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2. Neuro Oncol (2008) 1.07
Molecular subgroups of medulloblastoma. Expert Rev Neurother (2012) 1.05
MRI surrogates for molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol (2014) 1.04
Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape. J Clin Oncol (2015) 1.02
Urokinase-type plasminogen activator receptor (uPAR)-mediated regulation of WNT/β-catenin signaling is enhanced in irradiated medulloblastoma cells. J Biol Chem (2012) 1.02
Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol (2014) 1.01
Molecular diagnostics in embryonal brain tumors. Brain Pathol (2011) 1.00
The potential involvement of E-cadherin and beta-catenins in meningioma. PLoS One (2010) 0.97
Molecular insights into pediatric brain tumors have the potential to transform therapy. Clin Cancer Res (2014) 0.96
Clinical neuropathology practice guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. Clin Neuropathol (2013) 0.90
Cancer diagnosis marker extraction for soft tissue sarcomas based on gene expression profiling data by using projective adaptive resonance theory (PART) filtering method. BMC Bioinformatics (2006) 0.89
WNT3 inhibits cerebellar granule neuron progenitor proliferation and medulloblastoma formation via MAPK activation. PLoS One (2013) 0.86
Advances in managing medulloblastoma and intracranial primitive neuro-ectodermal tumors. F1000Prime Rep (2014) 0.86
Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation. Neuro Oncol (2011) 0.86
Identification of a neuronal transcription factor network involved in medulloblastoma development. Acta Neuropathol Commun (2013) 0.85
Wnt/beta-catenin signaling in cerebral cortical development. Organogenesis (2008) 0.85
The molecular genetics of medulloblastoma: an assessment of new therapeutic targets. Neurosurg Rev (2008) 0.85
Chronic viral infection and primary central nervous system malignancy. J Neuroimmune Pharmacol (2010) 0.84
WNT/β-catenin pathway activation in Myc immortalised cerebellar progenitor cells inhibits neuronal differentiation and generates tumours resembling medulloblastoma. Br J Cancer (2012) 0.84
Matching mice to malignancy: molecular subgroups and models of medulloblastoma. Childs Nerv Syst (2012) 0.83
Genetic and protein changes of E-cadherin in meningiomas. J Cancer Res Clin Oncol (2009) 0.83
Medulloblastoma: advances and challenges. F1000 Biol Rep (2011) 0.83
Chromosome 17 alterations identify good-risk and poor-risk tumors independently of clinical factors in medulloblastoma. Neuro Oncol (2011) 0.82
Genetic and molecular alterations across medulloblastoma subgroups. J Mol Med (Berl) (2015) 0.81
Characterization of ectonucleotidases in human medulloblastoma cell lines: ecto-5'NT/CD73 in metastasis as potential prognostic factor. PLoS One (2012) 0.81
Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial. Oncotarget (2015) 0.80
WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun (2014) 0.79
The role of the WNT/β-catenin pathway in central nervous system primitive neuroectodermal tumours (CNS PNETs). Br J Cancer (2013) 0.79
The role of stem cells and progenitors in the genesis of medulloblastoma. Exp Neurol (2012) 0.77
CTNNB1, AXIN1 and APC expression analysis of different medulloblastoma variants. Clinics (Sao Paulo) (2013) 0.77
WNT/β-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner. Oncogene (2017) 0.77
An interferon response gene expression signature is activated in a subset of medulloblastomas. Transl Oncol (2012) 0.76
Advances in paediatric cancer treatment. Transl Pediatr (2014) 0.76
Update on the integrated histopathological and genetic classification of medulloblastoma - a practical diagnostic guideline. Clin Neuropathol (2016) 0.76
Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities. J Pediatr Hematol Oncol (2016) 0.75
Ecto-5'-Nucleotidase Overexpression Reduces Tumor Growth in a Xenograph Medulloblastoma Model. PLoS One (2015) 0.75
Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. J Neurooncol (2016) 0.75
MR Imaging Characteristics of Wingless-Type-Subgroup Pediatric Medulloblastoma. AJNR Am J Neuroradiol (2015) 0.75
Modern management of medulloblastoma: Molecular classification, outcomes, and the role of surgery. Surg Neurol Int (2016) 0.75
Integrating RNA sequencing into neuro-oncology practice. Transl Res (2017) 0.75
An adult multifocal medulloblastoma with diffuse acute postoperative cerebellar swelling: immunohistochemical and molecular genetics analysis. Neurosurg Rev (2014) 0.75
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol (2010) 8.06
Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol (2011) 6.67
Subtypes of medulloblastoma have distinct developmental origins. Nature (2010) 5.94
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One (2008) 5.86
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol (2012) 3.88
Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol (2007) 3.47
Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol (2011) 2.82
Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle (2006) 2.37
Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol (2012) 2.34
The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev (2005) 2.14
Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol (2010) 2.04
Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol (2012) 2.01
Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol (2011) 2.01
Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res (2004) 1.67
Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior. Brain Pathol (2007) 1.59
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet (2003) 1.46
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol (2013) 1.43
Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Clin Cancer Res (2013) 1.37
Combined genome-wide allelotyping and copy number analysis identify frequent genetic losses without copy number reduction in medulloblastoma. Genes Chromosomes Cancer (2006) 1.35
MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol (2011) 1.33
Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res (2011) 1.33
Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma. PLoS One (2009) 1.33
Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathol (2011) 1.32
Temperature-driven Campylobacter seasonality in England and Wales. Appl Environ Microbiol (2005) 1.31
CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol (2014) 1.28
DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol (2013) 1.27
Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics (2006) 1.27
Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer (2005) 1.27
The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. Br J Neurosurg (2009) 1.27
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res (2009) 1.25
Analysis of patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study. Eur J Cancer (2006) 1.22
The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. Brain Res Mol Brain Res (2004) 1.17
What's new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol (2003) 1.16
Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adults but not children. Cell Cycle (2009) 1.13
Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis (2003) 1.13
Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol (2013) 1.12
Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. J Neuropathol Exp Neurol (2003) 1.11
Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. Neuro Oncol (2011) 1.10
Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2. Neuro Oncol (2008) 1.07
Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part II: Treatment-related late toxicity. Strahlenther Onkol (2003) 1.01
Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours. Int J Cancer (2006) 1.00
Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development. Cancer Res (2002) 0.99
Metastatic myxoid liposarcoma: aggressive multimodality management. Clin Oncol (R Coll Radiol) (2005) 0.99
Epigenetic events in medulloblastoma development. Neurosurg Focus (2005) 0.98
TP53 mutations in favorable-risk Wnt/Wingless-subtype medulloblastomas. J Clin Oncol (2011) 0.96
Treatment of recurrent central nervous system primitive neuroectodermal tumours in children and adolescents: results of a Children's Cancer and Leukaemia Group study. Eur J Cancer (2011) 0.95
Impact of radiotherapy parameters on outcome for patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study. Radiother Oncol (2009) 0.94
Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study. J Clin Oncol (2014) 0.94
Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastoma. Eur J Cancer (2006) 0.91
Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death. Acta Neuropathol (2011) 0.91
Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part I: Treatment modalities of radiation therapy. Strahlenther Onkol (2003) 0.91
The addition of high-dose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma. J Neurooncol (2010) 0.90
Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types. Acta Neuropathol (2013) 0.89
Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. Cancer Lett (2004) 0.87
Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer (2013) 0.86
Impact of radiotherapy parameters on outcome in the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study of preradiotherapy chemotherapy for M0-M1 medulloblastoma. Int J Radiat Oncol Biol Phys (2004) 0.86
Quantitative assessment of inter-clinician variability of target volume delineation for medulloblastoma: quality assurance for the SIOP PNET 4 trial protocol. Radiother Oncol (2003) 0.85
Identification of a neuronal transcription factor network involved in medulloblastoma development. Acta Neuropathol Commun (2013) 0.85
Survival after second primary neoplasms of the brain or spinal cord in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study. J Clin Oncol (2009) 0.85
Chromosome 1q gain is not associated with a poor outcome in childhood medulloblastoma: requirements for the validation of potential prognostic biomarkers. Cell Cycle (2009) 0.85
Identification and analysis of tumor suppressor loci at chromosome 10q23.3-10q25.3 in medulloblastoma. Cell Cycle (2006) 0.85
Genome-wide analysis of alternative splicing in medulloblastoma identifies splicing patterns characteristic of normal cerebellar development. Cancer Res (2011) 0.83